 The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc NASDAQ: ALLO AlloCAR T trials in response to an abnormality that could theoretically cause cancer. Related: Allogenes BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma. 